Japan's Ministry of Health has approved Joenja (leniolisib), an oral PI3K delta inhibitor, for treating activated PI3K delta syndrome (APDS) in patients aged 4 years and older. This marks the first treatment approved in Japan specifically for APDS and the first global approval for children aged 4 to 11 with the disease. Approval was based on positive Phase III clinical trial data showing significant improvements in immune function and disease symptoms. The drug is expected to launch in Japan after pricing agreement with the National Health Insurance system, offering a targeted treatment option for this rare immunodeficiency disorder.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
